Inflammatory Bowel Disease

Discussing the latest advances in Crohn’s disease and ulcerative colitis

Share this:
May 6th, 2016

FDA Approves of Biosimilar to Infliximab

By Kanaaz Pereira

The FDA recently approved of a biosimilar (CT-P13) to infliximab, which is used for treating IBD patients, as well as patients suffering from rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. The new drug would be the first biosimilar monoclonal antibody approved in the United States. Dr. Edward Loftus, M.D., explains how biosimilars work, and discusses some of the issues surrounding this medication, and its potential benefits and drawbacks.

For more information about IBD, visit mayoclinic.org/IBD.

Dr. Loftus is a gastroenterologist at Mayo Clinic.

Tags: biosimilar, CT-P13, Edward Loftus, FDA, IBD, infliximab, News Alerts, rheumatoid arthritis

Comment

Please login or register to post a comment.
Contact Us · Privacy Policy